Rotigotine: High-Affinity Dopamine D2/D3 Agonist for Parkinson's Disease Research

Executive Summary: Rotigotine is a selective dopamine D2 and D3 receptor agonist, exhibiting Ki values of 13 nM (D2) and 0.71 nM (D3) under standardized in vitro binding assays (Ouchi et al., 2022). It demonstrates significant antiparkinsonian activity by modulating micturition reflexes and voiding pressure in validated rat models. The compound also binds 5-HT1A and adrenergic α2B receptors, expanding its pharmacological profile. Rotigotine, available from APExBIO at ≥98% purity, is insoluble in water but dissolves readily in DMSO and ethanol. It is best suited for research on dopaminergic pathway function and Parkinson’s disease mechanisms (APExBIO).

Biological Rationale

Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to deficits in motor and non-motor function (Ouchi et al., 2022). Activation of dopamine D2 and D3 receptors is central to the regulation of motor and autonomic pathways, including control of the micturition reflex and bladder function. Lower urinary tract symptoms (LUTS) affect up to 63.9% of patients with PD, highlighting the importance of dopaminergic modulation in both central and peripheral systems. Rotigotine’s high affinity for D2/D3 receptors provides a robust tool for modeling and interrogating these pathways in preclinical and cellular assays. Its broad receptor profile makes it valuable for researchers investigating both canonical dopaminergic signaling and related serotonergic or adrenergic mechanisms (APExBIO).

Mechanism of Action of Rotigotine

Rotigotine acts as a full agonist at dopamine D2 and D3 receptors, mimicking endogenous dopamine and stimulating postsynaptic signaling cascades. Its sub-nanomolar to low-nanomolar Ki values indicate strong, selective binding in cell-based and membrane assays. Rotigotine also exhibits measurable affinity for 5-HT1A and adrenergic α2B receptors, which may contribute to its modulatory effects on non-motor symptoms and autonomic function. In vivo, systemic administration alters intercontraction intervals (ICI) and voiding pressure (VP), directly linking receptor activation to functional outcomes. These properties make Rotigotine a preferred tool for dissecting dopaminergic contributions to Parkinson’s disease phenotypes and for benchmarking new therapies targeting D2/D3 pathways (Ouchi et al., 2022).

Evidence & Benchmarks

• Rotigotine displays high D2 (Ki = 13 nM) and D3 (Ki = 0.71 nM) receptor affinity in radioligand binding assays (APExBIO).
• In 6-hydroxydopamine-induced rat PD models, intravenous Rotigotine at 0.25 or 0.5 mg/kg significantly reduced the intercontraction interval (ICI) compared to vehicle (p < 0.05) (DOI).
• Voiding pressure (VP) was significantly lowered in rats given 0.5 mg/kg Rotigotine intravenously versus vehicle controls (p = 0.028) (Ouchi et al., Table 1).
• Subcutaneous Rotigotine (0.125–0.5 mg/kg) increased ICI at 2 h post-injection; this effect was not seen with D1 receptor antagonist (+)-SCH23390, confirming D2/D3 specificity (DOI).
• Transdermal Rotigotine delivers stable plasma concentrations over 24 h in clinical settings, supporting use in chronic PD research (Ouchi et al., 2022).

This article extends the analyses in "Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson..." by providing new, peer-reviewed in vivo evidence of bladder function modulation, and clarifies mechanisms versus previous focus on workflow reproducibility. It updates "Rotigotine (SKU A3776): Reliable Dopamine Agonist for Par..." by integrating quantitative thresholds for dosing and response, and expands on "Rotigotine: Advanced Mechanistic Insights and Novel Exper..." by detailing benchmarked in vivo endpoints and highlighting boundaries for translational research.

Applications, Limits & Misconceptions

Rotigotine is widely used for:

• Modeling dopamine D2/D3 receptor-driven pathophysiology in preclinical PD studies.
• Benchmarking cell-based and in vivo assays of dopaminergic signaling.
• Investigating non-motor symptoms (e.g., LUTS) attributable to dopaminergic dysfunction.
• Pharmacological comparison with other receptor agonists in neuroprotection and pathway modulation.

Common Pitfalls or Misconceptions

• Rotigotine is not suitable for diagnostic or direct medical use; it is intended for research purposes only (APExBIO).
• It does not have significant water solubility (insoluble); use DMSO (≥58 mg/mL) or ethanol (≥25.25 mg/mL) as solvents.
• Long-term storage of solutions is not recommended due to stability limits; prepare fresh solutions for each experiment.
• The compound's affinity for 5-HT1A and α2B receptors may confound results in non-selective experimental contexts.
• Findings from rodent PD models may not fully extrapolate to human clinical efficacy without further validation.

Workflow Integration & Parameters

Rotigotine (SKU A3776) from APExBIO is provided as a crystalline solid of ≥98.00% purity. For experimental use, dissolve at concentrations up to 58 mg/mL in DMSO or 25.25 mg/mL in ethanol. Store powder at -20°C in a desiccated environment; avoid repeated freeze-thaw cycles. Use freshly prepared solutions to maximize activity and reproducibility. The compound’s robust performance has been validated in cell-based dopamine receptor activation assays and in vivo PD models using intravenous, subcutaneous, and transdermal routes.

For comparison and further mechanistic perspectives, see "Rotigotine and the Next Generation of Dopaminergic Modula...", which discusses translational strategies and molecular pharmacology, while this article details peer-reviewed in vivo pharmacodynamic endpoints and practical workflow integration.

Conclusion & Outlook

Rotigotine is a benchmark dopamine D2/D3 receptor agonist with validated antiparkinsonian effects in both cell-based and animal models. Its high purity, consistent receptor selectivity, and well-defined physicochemical parameters make it essential for rigorous Parkinson’s disease research and dopaminergic signaling studies. As the prevalence of PD rises among aging populations, robust research reagents like Rotigotine will remain crucial for translational discovery and therapeutic evaluation (Ouchi et al., 2022).

For complete specifications and ordering, visit the official Rotigotine A3776 product page at APExBIO.